LB Pharmaceuticals Inc
$31.67
▲
3.55%
2026-04-21 07:50:00
lbpharma.us
NGM: LBRX
Explore LB Pharmaceuticals Inc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$875.16 M
Current Price
$31.67
52W High / Low
$30.72 / $13.36
Stock P/E
—
Book Value
$11.91
Dividend Yield
—
ROCE
-9.95%
ROE
-15.7%
Face Value
—
EPS
$-3.13
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
27
Beta
—
Debt / Equity
1.18
Current Ratio
41.45
Quick Ratio
41.44
Forward P/E
-5.71
Price / Sales
—
Enterprise Value
$406.3 M
EV / EBITDA
-13.92
EV / Revenue
—
Rating
Strong Buy
Target Price
$45.75
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | SciSparc Ltd. | $4.23 | — | $2.5 M | — | -80.93% | -12.81% | $94.5 / $2.98 | $142.32 |
| 2. | Sensei Biotherapeutics, Inc. | $31.39 | — | $42.07 M | — | -119.5% | -74.01% | $36.76 / $5.25 | $18.24 |
| 3. | ADMA Biologics, Inc. | $10.88 | 17.68 | $2.6 B | — | 34.51% | 35.56% | $25.67 / $7.21 | $2.01 |
| 4. | Mustang Bio, Inc. | $0.74 | — | $5.61 M | — | -25.13% | -67.93% | $7 / $0.53 | $1.31 |
| 5. | Nuvalent, Inc. | $107.99 | — | $8.48 B | — | -31.35% | -36.7% | $113.02 / $63.55 | $15.96 |
| 6. | Atara Biotherapeutics, Inc. | $4.99 | 1.29 | $42.24 M | — | 674.99% | -48.15% | $19.14 / $3.92 | $-5.26 |
| 7. | MBX Biosciences, Inc. | $33.78 | — | $1.6 B | — | -26.53% | -27.76% | $44.89 / $7.09 | $8.22 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -13.87 M | -5.25 M | -5.54 M | -16.08 M |
| Net Profit | -11.47 M | -3.56 M | -5.07 M | -14.18 M |
| EPS in Rs | -0.4 | -0.12 | -0.18 | -0.49 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -30.4 M | -64.83 M | -11.38 M | -2.81 M |
| Net Profit | -25.2 M | -63.1 M | -6.28 M | -14.35 M |
| EPS in Rs | -0.88 | -2.2 | -0.22 | -0.5 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 312.93 M | 33.53 M | 45.66 M | 21.49 M |
| Total Liabilities | 11.62 M | 128.09 M | 80.13 M | 50.3 M |
| Equity | 301.31 M | -94.55 M | -34.47 M | -28.81 M |
| Current Assets | 308.43 M | 28.88 M | 45.63 M | 21.49 M |
| Current Liabilities | 7.44 M | 8.11 M | 2.61 M | 0.47 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -35.21 M | -53.05 M | -12.09 M | -2.73 M |
| Investing CF | -39.89 M | 23.23 M | -28.01 M | 0.12 M |
| Financing CF | 302.56 M | 38.31 M | 33.68 M | 22.96 M |
| Free CF | -35.26 M | -53.82 M | -12.12 M | -2.73 M |
| Capex | -0.05 M | -0.77 M | -0.03 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 60.06% | -905.61% | 56.27% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.